chrisvoncsefalvay/vaers-outcomes huggingface dataset:
felt clammy; dizzy/felt like I  was going to pass out; nauseous; extreme nausea; pain in my back; pain in my arms; sore injection site; red injection site; swollen injection site - about size of man's fist.; heavy fatigue; a bad headache/headpain; nausea; Dizziness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), BACK PAIN (pain in my back), PAIN IN EXTREMITY (pain in my arms), COLD SWEAT (felt clammy) and DIZZINESS (dizzy/felt like I  was going to pass out) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Brain injury (Has short term memory.), Shingles (two episodes of shingles) and Oxygen therapy since an unknown date. Previously administered products included for an unreported indication: HERPES SIMPLEX 2 VACCINE. Concurrent medical conditions included Immunocompromised, Asthma and Osteoporosis. Concomitant products included PREDNISONE for an unknown indication.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Apr-2021, the patient experienced DIZZINESS (Dizziness) and NAUSEA (nausea). On 11-Apr-2021, the patient experienced BACK PAIN (pain in my back), PAIN IN EXTREMITY (pain in my arms), VACCINATION SITE PAIN (sore injection site), VACCINATION SITE ERYTHEMA (red injection site), VACCINATION SITE SWELLING (swollen injection site - about size of man's fist.), FATIGUE (heavy fatigue), HEADACHE (a bad headache/headpain) and NAUSEA (extreme nausea). On 14-Apr-2021, the patient experienced COLD SWEAT (felt clammy), DIZZINESS (dizzy/felt like I  was going to pass out) and NAUSEA (nauseous). At the time of the report, DIZZINESS (Dizziness), BACK PAIN (pain in my back), PAIN IN EXTREMITY (pain in my arms), COLD SWEAT (felt clammy), DIZZINESS (dizzy/felt like I  was going to pass out), VACCINATION SITE PAIN (sore injection site), VACCINATION SITE ERYTHEMA (red injection site), VACCINATION SITE SWELLING (swollen injection site - about size of man's fist.), FATIGUE (heavy fatigue), HEADACHE (a bad headache/headpain), NAUSEA (nausea), NAUSEA (nauseous) and NAUSEA (extreme nausea) outcome was unknown.            Action taken with mRNA-1273 in response to the events was not applicable. Other concomitant medication included unspecified vitamins.
Entered a 10 kilometer run, which I had run in the past and arrived in the middle group.  This time I struggled to complete the run, I arrived last and could not get any more air in my lungs.  I finished and received my awards and while walking to my car coughed up some phlem which I and not done in the past.  The run started at 1030 in the morning and the temperatures were fine, as stated previously I have run the course before and never felt as winded and weak as I did that day.  I have since seen my Doctor who scheduled me for a TO-PFT PULM FUNCTION test performed 11 1230 MAY 22
11/10/2002, it was reported that a 48-year-old female, DOB 08/10/1953, received Imovax Rabies and Imogam USP on 07/08/2002. Dose 2 of Imovax Rabies was given on 07/11/2002. The pt did not report any adverse events following either the first or second doses of the series. Dose 3 was administered on 07/15/2002 in the right deltoid and dose 4 was administered on 07/22/2002 in the left deltoid. After the 3rd and 4th doses of the vaccine, the pt stated that her arm felt like it was bubbling and went completely numb immediately upon receiving the vaccine. After 10 minutes, the numbness started to subside. The following day, her arm was red and warm over an area measuring approx 4" long and 2" wide. Her physician told her it was an allergic reaction and advised her not to complete the series. She then called the Center for Disease Control and was advised to have a titer done. She then went to her physician and her titer on 07/23/2002 measured greater than 1:5. In August, she began to experience muscle cramps and an aching sensation in her legs, which occurred with or without activity. The pt stated that she normally walked 10-12 miles per day, but was only able to walk 2 miles because it hurt too much to walk. She experienced muscle spasms in her neck, right shoulder, and left arm. as well as hip joint pain. The pt stated that she was not sure if this report was ever submitted to VAERS. She believes all doses were Imovax. The lot number provided is from doses 2, 3 and 4. The lot number for the initial dose was not available. Dose one was administered at ERl It was not reported whether the pt recovered from these adverse events.
Pt. complained of left arm weakness 3 days after HPV vaccine injected.  Had initial stiffness for 2 days after vaccine.  No local reaction, no fever. Patient reported one episode of complete loss of sensation and motor function after sleeping on left arm which resolved with reintroduction of circulation.  Patient states that episode occured during first week following vaccine, patient not able to give exact date.
Rash at the injection site and extending from shoulder to elbow.  The arm also hurt, as if I were just injected.  It was an itcy rash. The rash appeared on Sunday, April 4, 2021--10 days after the injection. It began as small hives scattered over my arm, then increased to two large affected areas, each about 6 inches in length. Fourteen days after receiving the vaccine, a scab appeared at the injection site.
covid arm; COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine; COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine; COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine; COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE REACTION (covid arm), VACCINATION SITE SWELLING (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine), VACCINATION SITE ERYTHEMA (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine), VACCINATION SITE RASH (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine) and VACCINATION SITE PRURITUS (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Apr-2021, the patient experienced VACCINATION SITE REACTION (covid arm), VACCINATION SITE SWELLING (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine), VACCINATION SITE ERYTHEMA (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine), VACCINATION SITE RASH (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine) and VACCINATION SITE PRURITUS (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine). On 30-Apr-2021, VACCINATION SITE REACTION (covid arm), VACCINATION SITE SWELLING (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine), VACCINATION SITE ERYTHEMA (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine), VACCINATION SITE RASH (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine) and VACCINATION SITE PRURITUS (COVID arm (swelling, itchiness, redness, a bump - small circle) on her left arm - where shereceived the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication and treatment information were not provided.
uncomfortable; irritaed; Reoccurrence of itching at the injection site; Reoccurrence of redness at the injection site; itching; redness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (uncomfortable), SKIN IRRITATION (irritaed), VACCINATION SITE PRURITUS (Reoccurrence of itching at the injection site), VACCINATION SITE ERYTHEMA (redness at the injection site) and VACCINATION SITE ERYTHEMA (Reoccurrence of redness at the injection site) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (redness at the injection site). On an unknown date, the patient experienced MALAISE (uncomfortable), SKIN IRRITATION (irritaed), VACCINATION SITE PRURITUS (Reoccurrence of itching at the injection site), VACCINATION SITE ERYTHEMA (Reoccurrence of redness at the injection site) and VACCINATION SITE PRURITUS (itching). At the time of the report, MALAISE (uncomfortable), SKIN IRRITATION (irritaed), VACCINATION SITE PRURITUS (Reoccurrence of itching at the injection site), VACCINATION SITE ERYTHEMA (redness at the injection site), VACCINATION SITE ERYTHEMA (Reoccurrence of redness at the injection site) and VACCINATION SITE PRURITUS (itching) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication reported.   Treatment for the event included, ice, Benadryl.    This case was linked to MOD-2021-075764 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 16-Jan-2021: No specific follow-up information recorded. On 27-Jan-2021: No specific follow-up information recorded.; Sender's Comments:  MOD-2021-075764:Same patient, 2nd dose
drug Ineffective as after Covid 19 vaccine, the patient was diagnosed with Covid; drug Ineffective as after Covid 19 vaccine, the patient was diagnosed with Covid; This is a spontaneous report from a contactable consumer.   A male patient of an unspecified age received bnt162b2 (BNT162B2), dose 1, via an unspecified route of administration on 16Feb2021 (Batch/Lot number was not reported) as SINGLE DOSE for COVID-19 immunisation.  The patient's medical history and concomitant medications were not reported.  The reporter stated that she and her husband had the first vaccine on 16Feb2021 and set for Tuesday, 09Mar2021 for the second one. The reporter's husband has been diagnosed with Covid yesterday (07Mar2021) The reporter stated her husband has flu like symptoms which includes cough, sneezing, stuffy and no smell. The reporter reports for drug Ineffective as after Covid 19 vaccine, the patient was diagnosed with Covid. The reporter is asking if the patient should take the second dose next week. The outcome of the events was unknown.  Information about lot/batch no. has been requested
Patient received FLUZONE QUAD 2016-17 vaccine on 2-8-2017. The following day, she noticed stiffness and shoulder pain on the right side. She went to orthopedic doctor and was told it was frozen shoulder. Received a steroid shot from orthopedic doctor on 2/10/2017.
Examined 12/03/2002, c/o itchy bumps on back, no fever, cold cough. On exam 7 scabbed lesions on back
staph infection; This is a spontaneous report from a contactable consumer. A male patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported.  The patient is scheduled to get the second dose of the Pfizer COVID-19 vaccine tomorrow (26Mar2021). However, he had been on antibiotics for a month and a half and he wants to know if there would be any potential interaction with antibiotics and the vaccine. He said he had a staph infection (medically significant) and he had taken antibiotics intravenously for 3 weeks (on an IV line) and he is supposed to take oral antibiotics for 2 more weeks. The outcome of the event was unknown.   Information on the lot/ batch number has been requested.
The night I received the second dose, I was unable to sleep and had developed a fever. The next day I had the worst headache of my life and my body kept switching between feeling hot and cold. That night, I was able to sleep, but I woke up drenched in sweat. Day two after vaccination, I had a mild headache.
The pt experienced a 2cm area of redness, which was slightly warm around the Prevnar injection site on the left leg.
21SEP90; w/in 8-10 hrs of receiving vax, pt developed influenza-type sx & fever; Events resolved w/in 5 days; No known tx provided;
This spontaneous report as received from a health care worker refers to an unspecified number of patient of an unknown age and gender. On an unspecified date, unspecified number of patients were vaccinated with improperly stored (Oka/Merck) VARIVAX (Lot#, Strength, dose route were not reported) for an unknown indication. No adverse effects reported. No product quality complaint was involved. This is one of several reports received from the same reporter. Additional information has been requested.
No adverse event. Patient is 16 years old and was given Moderna, which is indicated for patients aged 18 years and older. No adverse events reported and patient will be given Moderna for second dose per CDC guidance.
Platelet count noted to be 51 at routine checkup, some bruising, no petechiae
Fever, chills, headache (not relieved by OTC med), muscle aches, dizziness,  swelling in arm and lymph nodes under arm (armpit), wheezing
Fever, chills, fatigue swelling in hands and feet at 24 hours. Followed by facial swelling (eyes/lip, blisters in mouth   took Advil only.  Lasted about 2 days.
day p/MMR, pt's  lt deltoid @ site of MMR was red, tender to touch & slightly edematous about 1 1/2 to 2" in diameter; no fever;
Difficulty breathing, winded, cant catch her breath; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Difficulty breathing, winded, cant catch her breath) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030A21A and 032B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DYSPNOEA (Difficulty breathing, winded, cant catch her breath). The patient was treated with PREDNISONE for Adverse event, at a dose of UNK dosage form. At the time of the report, DYSPNOEA (Difficulty breathing, winded, cant catch her breath) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, X-ray: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported Treatment medication includes: Inhaler   This case was linked to MOD-2021-239133 (Patient Link).
I had extreme pain in my left upper arm and shoulder. I could not move my left arm up and down without experiencing severe pain that lasted for about 10 days. My doctor prescribed Prednisone, and urgent care prescribed Naproxen. I felt extreme pain in most positions that I sat in or when I lay down. I could barely lift my left arm to a resting position on a table or sofa arm without extreme pain that caused me to wince and even brought tears to my eyes at times. I have never had a reaction even remotely similar to this with another vaccine and never expected it to be this painful. I was very concerned that my arm and shoulder might be permanently damaged. I still feel a twinge at times in my left shoulder when I lift something heavy or reach for something up high.
Fainting episode; Dehydration; Received 1st Moderna dose at age 14; This spontaneous case was reported by a pharmacist and describes the occurrence of SYNCOPE (Fainting episode) in a 14-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 25-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-May-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received 1st Moderna dose at age 14). On an unknown date, the patient experienced SYNCOPE (Fainting episode) (seriousness criterion medically significant) and DEHYDRATION (Dehydration). On 25-May-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received 1st Moderna dose at age 14) had resolved. At the time of the report, SYNCOPE (Fainting episode) and DEHYDRATION (Dehydration) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered SYNCOPE (Fainting episode) to be not related. No further causality assessments were provided for PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Received 1st Moderna dose at age 14) and DEHYDRATION (Dehydration).    No concomitant medications were provided. No treatment medications were provided.  Company Comment: This report refers to a case of product administered to patient of inappropriate age (14- year old) for mRNA-1273 (lot number 016C21A) with associated AEs reported as syncope and dehydration.   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: Follow-up received on 10 June 2021.Follow-up letter uploaded. New information included added events, including serious event of fainting. On 11-Jun-2021: Follow-up received on 11 June 2021.General tab information was updated (like information regarding the person completing form). In patient tab patient's height and weight was added.In product tab anatomical location was added.Events like syncope and dehydration were added in events tab.; Sender's Comments: This report refers to a case of product administered to patient of inappropriate age (14- year old) for mRNA-1273 (lot number 016C21A) with associated AEs reported as syncope and dehydration.
sleeping a lot - slept the whole week day and night for the first week; slight migraine a couple of days ago/migraines; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSOMNIA (sleeping a lot - slept the whole week day and night for the first week) and MIGRAINE (slight migraine a couple of days ago/migraines) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     The patient's past medical history included Mastectomy. Previously administered products included for Migraine: Imitrex. Concurrent medical conditions included Migraine.    On 18-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPERSOMNIA (sleeping a lot - slept the whole week day and night for the first week) and MIGRAINE (slight migraine a couple of days ago/migraines). The patient was treated with SUMATRIPTAN SUCCINATE (IMITREX [SUMATRIPTAN SUCCINATE]) for Migraine, at a dose of UNK dosage form and ACETYLSALICYLIC ACID, CAFFEINE, PARACETAMOL, SALICYLAMIDE (EXCEDRIN [ACETYLSALICYLIC ACID;CAFFEINE;PARACETAMOL;SALICYLAMIDE]) for Migraine, at a dose of UNK dosage form. On 12-Mar-2021, MIGRAINE (slight migraine a couple of days ago/migraines) had resolved. At the time of the report, HYPERSOMNIA (sleeping a lot - slept the whole week day and night for the first week) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.
Expected left arm pain and tiredness,flu like symptoms, but did not expect rapid heart beat at night or bad headache
Adopted infant with no known hlth problems brought in clinic for 1st immunizations, 1 1/2-2hrs following vaccine child had high pitched cry that lasted for 2-3hrs. No fever or seizure activity, lasted for 2-3 hrs. No fever or seizure activity. Parent had gone thru similar experience w. another adopted child who ???
I had very sore arm, headache, fever of 102, body aches and was very fuzzy headed. I was unable to concentrate or think. I didn't take anything for it, just allowed it to work. It was severe for a day and lasted for about 24-48. It completely resolved and I was able to return to work on the 2nd day. I did not see a doctor.
This spontaneous report was received from a pharmacist regarding 7 unspecified patients of unknown age and gender. No concomitant medication, medical history and allergies were reported for these patients. On an unknown date, the patients were vaccinated either with RECOMBIVAX HB (lot number and expiry date unknown) or VAQTA (lot number and expiry date unknown) series with a longer than recommended intervals between the doses on unspecified dates. Concomitant medications of the patient were not provided. No adverse event reported. Additional information has been requested.
This spontaneous report was received from a registered nurse regarding unknown number of patients with unknown demographics. Information on pertinent medical history, drug reactions/allergies and concomitant medications were not reported. On unknown dates, unknown number of doses of VAQTA (Lot# M022924 with expiry date: 24-JAN-2018, L015460 with expiry date: 20-JUL-2017, M015290 with expiry date: 20-SEP-2017) (dosing details were not reported) were administered to an unknown number of patients following a temperature excursion of 33 F for 23 days. No adverse effects were reported. No product quality complaint was reported. This is one of the several reports. Additional information is not expected as there is no consent to contact the reporter.
Bad Rash that cover from my neck ,down both arms , both chest and back area . Under arms and breast